Pentoxifylline in patients with oral submucous fibrosis-a randomized clinical trial
- PMID: 25729231
- PMCID: PMC4339328
- DOI: 10.1007/s12663-013-0580-x
Pentoxifylline in patients with oral submucous fibrosis-a randomized clinical trial
Abstract
Background and aim: As far as research regarding any disease is concerned, each and every aspect poses a challenge. One such entity that poses a challenge in our arena is oral submucous fibrosis (OSF) as no effective treatment is available for this progressively disabling condition with high malignant potential. Hence the present study was undertaken with the aim to determine the use of pentoxifylline (PTX) on the clinical and histopathologic course of OSF.
Method: Thirty clinically confirmed OSF patients were categorized randomly into group I and group II. In group I, drug PTX was administered as an adjunct along with other conventional therapies. Group II patients were advised conventional therapies only. Pre- and post-treatment biopsies were obtained for the following parameters:Micro-vascular density (MVD),Area percentage of blood vessels,Severity of fibrosis, andInflammatory components.
Results: On comparing MVD in groups I and II there was no significant difference in pre- and post-treatment.On comparing the average area percentage occupied by blood vessels, significant difference was seen in pre- and post-treatment biopsies in group I.On assessment of mouth opening and tongue protrusion, there was no significant improvement in either of the groups individually or in comparison. But when burning sensation of mucosa was assessed, pre- and post-treatment, both groups showed quite significant improvement individually.
Conclusion: Use of pentoxifylline seemed to be questionable, and taking into consideration the long administration time, its use is not recommended for the treatment of OSF patients.
Keywords: Blood vessels; Micro-vascular density; Oral submucous fibrosis; Pentoxifylline.
Figures




Similar articles
-
Drug treatment for oral submucous fibrosis: an update.BMC Oral Health. 2023 Oct 12;23(1):748. doi: 10.1186/s12903-023-03488-9. BMC Oral Health. 2023. PMID: 37828490 Free PMC article. Review.
-
Pentoxifylline - A Novel Adjunct in the Management of Patients with Oral Submucous Fibrosis in Terai Population of Nepal: A Prospective Case Control Study.Mymensingh Med J. 2022 Oct;31(4):1170-1178. Mymensingh Med J. 2022. PMID: 36189568
-
Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis.Indian J Dent Res. 2006 Oct-Dec;17(4):190-8. doi: 10.4103/0970-9290.29865. Indian J Dent Res. 2006. PMID: 17217216 Clinical Trial.
-
In vivo autofluorescence characteristics of pre- and post-treated oral submucous fibrosis: a pilot study.Indian J Dent Res. 2009 Jul-Sep;20(3):261-7. doi: 10.4103/0970-9290.57354. Indian J Dent Res. 2009. PMID: 19884705 Clinical Trial.
-
Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: A meta-analysis.Oral Dis. 2018 Jul;24(5):706-716. doi: 10.1111/odi.12715. Epub 2017 Aug 22. Oral Dis. 2018. PMID: 28737007 Review.
Cited by
-
Conservative management of Oral Submucous Fibrosis in early and intermediate stage.J Oral Biol Craniofac Res. 2018 May-Aug;8(2):86-88. doi: 10.1016/j.jobcr.2017.06.002. Epub 2017 Jun 19. J Oral Biol Craniofac Res. 2018. PMID: 29892527 Free PMC article.
-
Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.Physiol Rev. 2022 Apr 1;102(2):605-652. doi: 10.1152/physrev.00005.2021. Epub 2021 Sep 27. Physiol Rev. 2022. PMID: 34569264 Free PMC article. Review.
-
Drug treatment for oral submucous fibrosis: an update.BMC Oral Health. 2023 Oct 12;23(1):748. doi: 10.1186/s12903-023-03488-9. BMC Oral Health. 2023. PMID: 37828490 Free PMC article. Review.
-
Comparison of triamcinolone with pentoxifylline and vitamin E efficacy in the treatment of stage 2 and 3 oral submucous fibrosis: A randomized clinical trial.SAGE Open Med. 2023 Sep 29;11:20503121231200757. doi: 10.1177/20503121231200757. eCollection 2023. SAGE Open Med. 2023. PMID: 37786898 Free PMC article.
-
Evaluating the Oral-Health-Related Quality of Life of Oral Submucous Fibrosis Patients before and after Treatment Using the OHIP-14 Tool.Int J Environ Res Public Health. 2022 Feb 5;19(3):1821. doi: 10.3390/ijerph19031821. Int J Environ Res Public Health. 2022. PMID: 35162842 Free PMC article. Clinical Trial.
References
-
- Mehrotra R, Singh HP, Gupta SC, Singh M, Jain S. Pentoxifylline therapy in the management of oral submucous fibrosis. Asian Pac J Cancer Prev. 2011;12:971–974. - PubMed
-
- Reddy V, Wanjari PV, Banda NR, Reddy P. Oral submucous fibrosis: correlation of clinical grading to various habit factors. Int J Dent Clin. 2011;3(1):21–24. doi: 10.4103/2231-0754.115770. - DOI
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials